Home/ Stocks/ INBX

Inhibrx Biosciences, Inc. Common Stock

INBX XNAS

$114.12 +30.04 (+35.73%) ▲ 15-min delayed

Open

$147.50

High

$155.29

Low

$100.00

Volume

2.17M

Market Cap

$1.23B

About Inhibrx Biosciences, Inc. Common Stock

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 110 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$1.30M	$-140,055,000	$-9.04
FY 2025	$1.30M	$-140,055,000	$-9.04
Q3 2025	$0	$-35,256,000	$-2.28
Q1 2025	$0	$-43,311,000	$-2.80

Earnings & Analyst Ratings

Next Earnings: Wed, May 20, 2026

Calendar →

TickerDaily Coverage

Why Is Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Up 76.6% Today?

Market News Sarah Mitchell · 3h ago

Inhibrx Biosciences (INBX) stock ripped higher 76.6% on Wednesday, April 22, 2026, closing at...

View All Coverage →

Get INBX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Inhibrx Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.